Plus   Neg

Endocyte: Phase 2b TARGET Trial Results Show Improved Survival In NSCLC Patients

Endocyte, Inc. (ECYT) announced that the small molecule drug conjugate or SMDC vintafolide in combination with docetaxel extended overall survival or OS for patients with folate receptor or FR positive recurrent non-small cell lung cancer or NSCLC compared with patients receiving monotherapy docetaxel in its TARGET Phase 2b study. The late-breaking TARGET trial data would be presented at the European Society for Medical Oncology Congress or ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.

The data show that patients in the predefined adenocarcinoma subgroup treated with the vintafolide plus docetaxel combination had a 27 percent reduction in risk of the disease worsening or death, and a 30 percent reduction in the risk of death compared to docetaxel monotherapy.

Rohit Lal said, "These results are very promising for patients receiving second-line treatment for this challenging disease. The folate receptor is a promising target, particularly in NSCLC, where the majority of patients are positive for this receptor. In particular, the consistency of results among patients with adenocarcinoma, including improved tumor response, delayed disease progression, and extended overall survival, support continued study of vintafolide in this patient population."

The study enrolled and treated 199 patients whose target tumors were all positive for the folate receptor, as determined with the companion imaging agent etarfolatide. Patients were randomized between three arms: vintafolide monotherapy, a combination of vintafolide and docetaxel, and docetaxel monotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumer goods giant Procter & Gamble Co. on Wednesday reported a 28 percent increase in profit for the second quarter from last year, when results were impacted by a charge related to the U.S. tax reform. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company affirmed its outlook for fiscal 2019 earnings. LSEG Technology, London Stock Exchange Group's technology solutions provider, said it has been selected by Atom Group, a fintech company focused on blockchain technology and emerging digital assets, to power its new Hong Kong-based digital asset exchange AAX. The new digital exchange, which is expected to launch in the first half of fiscal 2019, will use LSEG's Millennium Exchange matching engine. Starbucks Coffee Co. said Tuesday it is expanding its "Starbucks Delivers" pilot to an additional six cities across the U.S. The expansion of the delivery service, in partnership with Uber Eats, begins today in San Francisco, the first of six new markets to offer the service to customers. The coffee giant plans to bring Starbucks Delivers to nearly one-quarter of U.S. company-operated stores.